Welcome to our dedicated page for Gilead Sciences SEC filings (Ticker: GILD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gilead Sciences, Inc. (Nasdaq: GILD) is a Delaware‑incorporated biopharmaceutical company whose common stock is registered on The Nasdaq Global Select Market. As an SEC‑reporting issuer, Gilead files a range of regulatory documents that provide detailed insight into its financial condition, governance and material events. This page aggregates GILD’s SEC filings and pairs them with AI‑generated summaries to help readers understand the key points in complex disclosures.
For Gilead, Form 10‑K annual reports and Form 10‑Q quarterly reports are central sources of information on its HIV, viral hepatitis, COVID‑19, oncology and inflammation businesses, including segment discussions, risk factors and research and development spending. Form 8‑K current reports capture specific developments such as quarterly financial results, amendments to bylaws, executive leadership changes and significant agreements. Recent 8‑K filings, for example, have disclosed financial results for particular quarters, updates to the company’s bylaws governing director nominations and stockholder proposals, patent settlements related to Biktarvy, and changes in senior corporate affairs and legal roles.
Investors can also use this page to access proxy statements for information on board structure and executive compensation, and Form 4 insider transaction reports to track trades by directors and officers. Because Gilead is not classified as an emerging growth company, its filings follow the full disclosure requirements applicable to large, established issuers.
Stock Titan enhances GILD filings with AI‑powered explanations that highlight material items, translate technical accounting and legal language into plain terms, and surface topics such as governance changes, litigation updates or collaboration agreements. Real‑time ingestion from EDGAR means new Gilead filings appear quickly, while the AI layer helps readers focus on what changed, why it matters for the company’s HIV, antiviral and oncology franchises, and how it may affect shareholders.
Gilead Sciences insider notice for proposed Rule 144 sale. The filing reports a proposed sale of 28,000 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $3,318,924.65 and the company’s outstanding shares listed as 1,240,806,916. The filer shows recent acquisitions including a 25,000-share stock option exercise dated 08/15/2025, 2,394 performance shares (01/31/2024) and 606 restricted shares (12/10/2023). The form also lists multiple dispositions by Johanna Mercier in the past three months, with individual sales and gross proceeds disclosed for each trade.
Gilead Sciences filed a Form 13F reporting its institutional holdings as manager. The filing lists 14 holdings with a total reported market value of $1,280,204,668. The report is signed by Andrew D. Dickinson, Executive Vice President and Chief Financial Officer, dated 08-14-2025.